138 related articles for article (PubMed ID: 19200026)
1. The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders.
Juillerat-Jeanneret L; Gerber-Lemaire S
Mini Rev Med Chem; 2009 Feb; 9(2):215-26. PubMed ID: 19200026
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.
Edosada CY; Quan C; Wiesmann C; Tran T; Sutherlin D; Reynolds M; Elliott JM; Raab H; Fairbrother W; Wolf BB
J Biol Chem; 2006 Mar; 281(11):7437-44. PubMed ID: 16410248
[TBL] [Abstract][Full Text] [Related]
3. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.
Rosenblum JS; Kozarich JW
Curr Opin Chem Biol; 2003 Aug; 7(4):496-504. PubMed ID: 12941425
[TBL] [Abstract][Full Text] [Related]
4. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
Chen SJ; Jiaang WT
Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
[TBL] [Abstract][Full Text] [Related]
5. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.
Van der Veken P; Haemers A; Augustyns K
Curr Top Med Chem; 2007; 7(6):621-35. PubMed ID: 17352682
[TBL] [Abstract][Full Text] [Related]
6. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.
Tsai TY; Yeh TK; Chen X; Hsu T; Jao YC; Huang CH; Song JS; Huang YC; Chien CH; Chiu JH; Yen SC; Tang HK; Chao YS; Jiaang WT
J Med Chem; 2010 Sep; 53(18):6572-83. PubMed ID: 20718420
[TBL] [Abstract][Full Text] [Related]
7. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
Stremenová J; Mares V; Lisá V; Hilser M; Krepela E; Vanicková Z; Syrucek M; Soula O; Sedo A
Int J Oncol; 2010 Feb; 36(2):351-8. PubMed ID: 20043068
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?
Juillerat-Jeanneret L; Tafelmeyer P; Golshayan D
Expert Opin Ther Targets; 2017 Oct; 21(10):977-991. PubMed ID: 28829211
[TBL] [Abstract][Full Text] [Related]
9. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8.
Abbott CA; Yu DM; Woollatt E; Sutherland GR; McCaughan GW; Gorrell MD
Eur J Biochem; 2000 Oct; 267(20):6140-50. PubMed ID: 11012666
[TBL] [Abstract][Full Text] [Related]
10. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.
Wagner L; Klemann C; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jun; 184(3):265-83. PubMed ID: 26671446
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
12. Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer.
Kotacková L; Baláziová E; Sedo A
Folia Biol (Praha); 2009; 55(3):77-84. PubMed ID: 19545486
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer.
Busek P; Malík R; Sedo A
Int J Biochem Cell Biol; 2004 Mar; 36(3):408-21. PubMed ID: 14687920
[TBL] [Abstract][Full Text] [Related]
14. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
[TBL] [Abstract][Full Text] [Related]
15. Seprase complexes in cellular invasiveness.
Chen WT; Kelly T
Cancer Metastasis Rev; 2003; 22(2-3):259-69. PubMed ID: 12785000
[TBL] [Abstract][Full Text] [Related]
16. In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine).
De Meester I; Belyaev A; Lambeir AM; De Meyer GR; Van Osselaer N; Haemers A; Scharpé S
Biochem Pharmacol; 1997 Jul; 54(1):173-9. PubMed ID: 9296364
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas.
Matrasova I; Busek P; Balaziova E; Sedo A
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):252-260. PubMed ID: 28452380
[TBL] [Abstract][Full Text] [Related]
18. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
Ryabtsova O; Jansen K; Van Goethem S; Joossens J; Cheng JD; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
Bioorg Med Chem Lett; 2012 May; 22(10):3412-7. PubMed ID: 22525314
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of the homologous proteases fibroblast activation protein and dipeptidyl peptidase-IV in the adult human Langerhans islets.
Busek P; Hrabal P; Fric P; Sedo A
Histochem Cell Biol; 2015 May; 143(5):497-504. PubMed ID: 25361590
[TBL] [Abstract][Full Text] [Related]
20. The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.
Waumans Y; Baerts L; Kehoe K; Lambeir AM; De Meester I
Front Immunol; 2015; 6():387. PubMed ID: 26300881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
